CVR: 17981994
Secondary names: Norpharma A/S
Previous names: A/S PSE 10 NR. 2061, NORPHARMA A/S, Norpharma A/S
Mundipharma A/S is experiencing a declining trend in revenue and profitability, with revenues decreasing from 48.5 million DKK in 2021 to 25.9 million DKK in 2025. Profit margins have also contracted, with profits falling from 909,000 DKK in 2021 to 672,000 DKK in 2025. The company's equity position remains relatively stable, increasing slightly from 36.98 million DKK in 2023 to 38.17 million DKK in 2025, indicating some resilience. However, the overall trajectory suggests challenges in maintaining market position within the pharmaceutical distribution industry.
AI-generated summary
Selskabets formål er at drive handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 25.9 mio. | 672 t. | 51.4 mio. | 38.2 mio. | 3 | |
Compared to 411 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
1 public tender won
Sources: TED (the EU tender database) and udbud.dk
Bryan George Lea joined the board
Elliot James Haddock left the board
Elliot James Haddock joined the board
Sarah Anna Heidrich left the board
Companies in the same industry and area
CVR 34362440
CVR 37642185
CVR 44558254
CVR 59238213
CVR 32122337
companydata.dk